Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq:CSTL) reported prospective, multicenter DECIDE study results showing its DecisionDx-Melanoma i31-SLNB risk prediction outperformed the MIA nomogram for sentinel lymph node (SLN) positivity in cutaneous melanoma.
In 912 patients, i31-SLNB low-risk cases had 2.6% observed SLN positivity vs 5.8% for MIA; overall AUC was 0.74 vs 0.61 (p=0.001).
Castle Biosciences (Nasdaq:CSTL) announced that chief financial officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. He is one of 22 CFOs recognized in Greater Houston for financial leadership and organizational impact.
Stokes has served as CFO since December 2017, helping guide Castle Biosciences’ 2019 Nasdaq IPO and supporting growth through multiple strategic acquisitions. Honorees will be celebrated July 30 and featured in the July 31 print and digital issues.
Castle Biosciences (Nasdaq:CSTL) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4). On June 15, 2026, its Compensation Committee granted RSUs covering 204,925 shares of common stock to 172 new employees under the 2022 Inducement Plan, vesting over four years.
Castle Biosciences (Nasdaq:CSTL) announced that its AI-derived TissueCypher Barrett's Esophagus Test has exceeded 100,000 clinical orders as of June 16, 2026. The test is designed to predict a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, helping clinicians tailor management decisions.
Castle Biosciences (Nasdaq:CSTL) announced that executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live audio webcast and replay will be accessible via the company’s website.
Castle Biosciences (Nasdaq:CSTL) announced that its AdvanceAD-Tx test won the 2026 MedTech Breakthrough Genomics Innovation Award, the company’s fifth MedTech Breakthrough honor.
AdvanceAD-Tx is a clinically validated, non-invasive gene expression profile test guiding systemic treatment selection for patients 12+ with moderate-to-severe atopic dermatitis, supported by prospective multi-center data on skin clearance and symptom relief.
Castle Biosciences (Nasdaq: CSTL) reported Q1 2026 revenue of $83.7 million and raised full-year 2026 revenue guidance to $345–355 million from $340–350 million. Core test reports (DecisionDx-Melanoma, TissueCypher) grew 36% year-over-year; DecisionDx-Melanoma test reports were 10,021.
Gross margin was 73% (Adjusted Gross Margin 76%), adjusted EBITDA was a $5.1 million loss, and cash plus investments totaled $261.7 million as of March 31, 2026.
Castle Biosciences (Nasdaq: CSTL) is supporting nationwide patient advocacy, community screenings and education throughout May for Skin Cancer Awareness Month. Activities include advocacy walks, symposiums at Fred Hutch, Ohio State (May 9) and Yale (May 12), a May 26 webinar, Sun Bus skin checks (May 15–16) and participation in Nevada’s Biggest Little Skin Check (May 14).
The company partners with AIM at Melanoma, Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus to expand access to early detection and patient education.
Castle Biosciences (NASDAQ:CSTL) announced Mayo Clinic data presented at DDW 2026 showing the TissueCypher test refines risk stratification and informs risk-aligned surveillance for Barrett's esophagus.
In multicenter cohorts, physicians changed surveillance intervals in 55% of patients and aligned recommendations with TissueCypher risk in 79%; TissueCypher classified 84% as low risk versus 38% by a clinical model (κ=0.04).
Castle Biosciences (Nasdaq: CSTL) will present new DecisionDx-Melanoma data at EADO (Apr 23-25, 2026) and ACMS (Apr 30–May 3, 2026).
Multi-center and SEER population analyses show the 31-gene expression profile provides prognostic information beyond AJCC staging, identifying higher-risk patients among thin and early-stage melanoma who may benefit from intensified management.